版本:
中国

BRIEF-Bempedoic Acid Global phase 3 clinical program to include patients on any Statin at any dose

Oct 13 Esperion Therapeutics Inc :

* Bempedoic acid global phase 3 clinical program to include patients on any statin at any dose

* Esperion Therapeutics Inc - top-line results from 1002-035 demonstrated eight-week study met its primary endpoint

* Esperion Therapeutics - "focused on initiating both bempedoic acid global phase 3 efficacy program, cardiovascular outcomes study before year-end"

* Esperion Therapeutics Inc says also announced positive top-line results from its phase 1, open-label, clinical pharmacology study (1002-037)

* Esperion Therapeutics Inc- bempedoic acid appeared to be safe and well-tolerated, with no serious adverse events reported Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐